These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37956521)

  • 1. Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
    Roar M; Nielsen ARH; Berg JM; Sirakov G; Stilund M; Schäfer J; Ratzer R; Frederiksen J; Asgari N; Ashna SN; Jensen HB; Kant M; Theódorsdóttir Á; Illes Z; Sellebjerg F; Magyari M; Schlosser LM; Nordborg H; Wergeland S; Sejbaek T
    Mult Scler Relat Disord; 2023 Dec; 80():105127. PubMed ID: 37956521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
    Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
    Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
    Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
    Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
    Vural E; Engin E; Sünter G; Yıldırım KA; Günal D
    Turk J Med Sci; 2023 Jun; 53(3):771-779. PubMed ID: 37476900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
    J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
    Chu L; Balusha A; Casserly C; Berger W; Morrow SA
    Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
    Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
    Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T
    Ann Neurol; 2022 May; 91(5):676-681. PubMed ID: 35170072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Caldito NG; O'Leary S; Stuve O
    Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
    Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE™ support program.
    Thompson MT; Virginia D; Nick B; Melissa G; Engineer N; Shen C; Reedie S
    Mult Scler Relat Disord; 2022 Nov; 67():104080. PubMed ID: 35973386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S
    Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.